Kaitai Capital
VC Fund
Hangzhou, China
Kaitai Capital is a VC fund in Hangzhou focused on Biotechnology and Health Care. KAITAI CAPITAL, founded in 2009, is a professional investment management organization that mainly engaged in innovative investment, industrial investment, and wealth management business. Fields of investment include biopharma, healthcare services, agriculture tech, consumer business, digital technology and etc.
- Total investments:
- 147
- Last investment:
- Lead investor:
- 30%
Last updated:
For AI agents: llms.txt
Industries Kaitai Capital invests in
Stages Kaitai Capital invests in
Countries Kaitai Capital invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $2.4M–$20M
- Series A
- $1.4M–$35M
- Series B
- $10M–$57M
Investment Focus
Industry
- Biotechnology 52 (35%)
- Health Care 35 (24%)
- Pharmaceutical 30 (20%)
- Medical 22 (15%)
- Artificial Intelligence 16 (11%)
Stage
- Series A 41 (28%)
- Series B 22 (15%)
- Seed 21 (14%)
- Angel 18 (12%)
- Venture - Series Unknown 16 (11%)
Country
- China 90 (61%)
- United States 21 (14%)
- Singapore 1 (1%)
- United Kingdom 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Huang Zehua
Partner
|
Partner | Total investments: 4 | Find email | |
|
Jin Qi
Managing Partner
|
Managing Partner | Total investments: 1 | Find email | |
|
Li Xianxian
Managing Partner
|
Managing Partner | Total investments: 1 | Find email | |
|
Nannan Chang
Senior Investment Manager
|
Senior Investment Manager | Total investments: 4 | Find email | |
Xian Li
Partner
|
Partner | Total investments: 1 | Find email | |
| See all 7 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
|
Yushi Space
|
Yushi Space is a liquid rocket developer that focuses on the development and manufacture of large-capacity, low-cost and rapidly reusable liquid rockets. | $73.4M / Series A / May 18, 2026 | |
PaXini Tech
|
All Scenario Application—Haptic Digitization and Tactile Technology | $145.1M / Series B / Mar 05, 2026 | |
Deep Intelligent Pharma
|
Deep Intelligent Pharma (DIP) is a Singapore-based AI company that helps pharmaceutical and biotech companies run clinical trials faster, cheaper, and with fewer mistakes. Its AI platform automates many slow and manual tasks, such as writing trial documents, designing studies, analyzing data, translating medical content for global regulators, andpreparing regulatory submissions. By using thousands of small AI agents supervised by experts, DIP not only saves time but also helps improve the chance that a clinical trial will succeed. Its technology has already been proven in real cases, including an AI-written protocol approved by Japan’s regulator with no revisions. Today, DIP works with over 1,000 life science companies worldwide, including major names like Bayer, Johnson & Johnson, and Roche. | $40M / Venture - Series Unknown / Mar 04, 2026 | |
|
Deep Intelligent Pharma
|
Deep Intelligent Pharma (DIP) is a Singapore-based AI company that helps pharmaceutical and biotech companies run clinical trials faster, cheaper, and with fewer mistakes. Its AI platform automates many slow and manual tasks, such as writing trial documents, designing studies, analyzing data, translating medical content for global regulators, andpreparing regulatory submissions. By using thousands of small AI agents supervised by experts, DIP not only saves time but also helps improve the chance that a clinical trial will succeed. Its technology has already been proven in real cases, including an AI-written protocol approved by Japan’s regulator with no revisions. Today, DIP works with over 1,000 life science companies worldwide, including major names like Bayer, Johnson & Johnson, and Roche. | $60M / Series D / Feb 02, 2026 | |
|
Junsai Shengwu
|
Junsai Shengwu developes therapies for new solid tumor cell. | $19.2M / Series C / Nov 01, 2025 | |
OncoC4
|
OncoC4 is a clinical-stage biotechnology company that is actively engaged in the discovery and development of novel biologics for the potential treatment of cancer and neurodegenerative disease. | $50M / Series B / Oct 02, 2025 | |
|
Huaboron Neutron
|
Huaboron Neutron is a biotechnology company that develops boron drugs and boron neutron capture therapy devices for the diagnosis of malignant cancers. | Seed / Aug 22, 2025 | |
|
Sheng Sheng Biology
|
Sheng Sheng Biology is a biotechnology company that provides medical research and experimental development services. | Series A / Nov 21, 2024 | |
Xinyue
|
Yuejing Network Technology Co., Ltd. is a digital video assistant platform that cuts in the communication and review links in the video production stream, helping to achieve multi-platform preview of video demos in video production and convenient review comments and video storage. sort out. With the subsequent connection of external hardware, theuser can realize the real-time synchronization of the video data captured in the camera to the new cloud server, and later can synchronize production and storage sharing through the new reading. | $1.4M / Series A / May 11, 2024 | |
TechnoDerma Medicines
|
TechnoDerma Medicines focuses on the research and development of innovative skin drugs for external use. | Series A / Jan 15, 2024 | |
| See all 147 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Kaitai Capital invest in?
Kaitai Capital invests primarily in Biotechnology, Health Care and Pharmaceutical startups, most often at Series A and Series B stage. Most of the 147 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Kaitai Capital's check size?
Kaitai Capital typically joins rounds of $2.4M–$20M at Seed, $1.4M–$35M at Series A and $10M–$57M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Kaitai Capital participates in.
How do I contact Kaitai Capital?
Public channels for Kaitai Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Kaitai Capital?
The team at Kaitai Capital includes Huang Zehua (Partner), Jin Qi (Managing Partner) and Li Xianxian (Managing Partner), among 7 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
